Onco-immunotherapies, such as immune checkpoint blockade inhibitors and adoptive

by | Sep 24, 2022 | Pharmacology | 0 comments

Onco-immunotherapies, such as immune checkpoint blockade inhibitors and adoptive cell therapies, are revolutionizing the field of cancer therapy due to their ability to induce strong anti-tumor immune responses. Many novel immune-based cancer therapies are rapidly moving from the bench to the clinic. However, despite being very effective in hematological and some solid tumors, unresponsiveness, development of therapy resistance, and serious adverse effects limit their capacity to impact the vast majority of solid tumors. The use of nanoparticle-based delivery systems (NPs) to improve conventional onco-immunotherapies is gaining traction due largely to the versatility of this approach; these systems can be loaded with a wide variety of molecular cargoes and finely tuned to release their contents into the tumor microenvironment. NPs can be engineered to deliver combinations of adjuvants and antigens, as in the case of nanovaccines. This Special Issue aims to collect manuscripts related to the development of novel nanotherapeutics to remodel the tumor microenvironment and enhance immunotherapies for the treatment of solid tumors.

Do you need any assistance with this question?
Send us your paper details now
We'll find the best professional writer for you!